On Aug. 19, 2024, an international team of scientists led by researchers from the Translational Genomics Research Institute (TGen) announced an unprecedented effort to sequence the genome, exome and RNA in tumors from patients with multiple myeloma defines distinct subtypes of the disease.

The findings of the 12-year observational study provided a clearer picture of the genetic changes that may be important in each subtype of this cancer of our antibody producing plasma cells, which is treatable but incurable. This information could help guide more personalized treatments in the future. The study results were published in Nature Genetics.